- Home
- TROX vs PVLA Comparison
TROX vs PVLA Comparison
Compare TROX & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TROX
- PVLA
- Stock Information
- Founded
- TROX 2018
- PVLA 2015
- Country
- TROX United States
- PVLA United States
- Employees
- TROX N/A
- PVLA N/A
- Industry
- TROX Major Chemicals
- PVLA Biotechnology: Pharmaceutical Preparations
- Sector
- TROX Industrials
- PVLA Health Care
- Exchange
- TROX Nasdaq
- PVLA Nasdaq
- Market Cap
- TROX 640.4M
- PVLA 604.2M
- IPO Year
- TROX 2005
- PVLA N/A
- Fundamental
- Price
- TROX $4.05
- PVLA $73.52
- Analyst Decision
- TROX Hold
- PVLA Strong Buy
- Analyst Count
- TROX 8
- PVLA 12
- Target Price
- TROX $4.77
- PVLA $68.67
- AVG Volume (30 Days)
- TROX 4.6M
- PVLA 219.3K
- Earning Date
- TROX 11-05-2025
- PVLA 11-15-2025
- Dividend Yield
- TROX 4.91%
- PVLA N/A
- EPS Growth
- TROX N/A
- PVLA N/A
- EPS
- TROX N/A
- PVLA N/A
- Revenue
- TROX $2,949,000,000.00
- PVLA N/A
- Revenue This Year
- TROX N/A
- PVLA N/A
- Revenue Next Year
- TROX $3.93
- PVLA N/A
- P/E Ratio
- TROX N/A
- PVLA N/A
- Revenue Growth
- TROX 0.24
- PVLA N/A
- 52 Week Low
- TROX $2.95
- PVLA $11.17
- 52 Week High
- TROX $14.93
- PVLA $76.76
- Technical
- Relative Strength Index (RSI)
- TROX 49.48
- PVLA 65.48
- Support Level
- TROX $3.32
- PVLA $65.93
- Resistance Level
- TROX $4.15
- PVLA $76.28
- Average True Range (ATR)
- TROX 0.28
- PVLA 4.45
- MACD
- TROX -0.04
- PVLA 0.63
- Stochastic Oscillator
- TROX 71.94
- PVLA 81.32
About TROX Tronox Holdings plc (UK)
Tronox Holdings PLC is a vertically integrated manufacturer of TiO2 pigment. It operates titanium-bearing mineral sand mines and beneficiation and smelting operations in Australia & South Africa to produce feedstock materials that can be processed into TiO2 for pigment, high-purity titanium chemicals, including titanium tetrachloride, and ultrafine TiO2 used in certain specialty applications. TiO2 and titanium feedstock, are used to produce paints and coatings, as well as plastics, paper, and printing ink. It has three pigment production facilities in the United States, the Netherlands, and Western Australia and three mining operations in Western Australia and South Africa. Europe, the Middle East, and Africa regions contribute the majority of revenue.
About PVLA Palvella Therapeutics Inc. Common Stock
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.